Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

BGE-102

Source date not recordedAnalyse record ↗

Investigational oral NLRP3 inhibitor being studied for inflammation associated with cardiovascular risk and diabetic macular edema.

Modality
oral brain-penetrant small-molecule NLRP3 inhibitor
Availability (US)
Phase 2 clinical development
Biomarkers
hsCRP; IL-1 beta; IL-6; fibrinogen; pharmacokinetics; NLRP3 target inhibition
Hallmark targeted
chronic inflammation, altered intercellular communication, metabolic aging
Kind
investigational drug
Clinical trials
QUELL-CV Phase 2 study in adults with elevated systemic inflammation and cardiovascular risk; diabetic-macular-edema Phase 2 program